Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. 詳細を表示
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration PR Newswire SAN FRANCISCO and SUZHOU, China, Dec. 20...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder...
Submitted New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in October for the treatment of patients with advanced ROS1-positive (ROS1+) non-small cell...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1 | 3.81679389313 | 2.62 | 2.865 | 2.51 | 2664107 | 2.688133 | CS |
4 | 0.01 | 0.369003690037 | 2.71 | 3.05 | 2.51 | 2336629 | 2.78385554 | CS |
12 | 0.23 | 9.23694779116 | 2.49 | 3.08 | 2 | 2083348 | 2.60610832 | CS |
26 | -0.18 | -6.20689655172 | 2.9 | 3.97 | 2 | 1808386 | 2.81568788 | CS |
52 | 1.26 | 86.301369863 | 1.46 | 4.1598 | 1.395 | 1514221 | 2.78523577 | CS |
156 | -5.67 | -67.5804529201 | 8.39 | 8.88 | 0.95 | 1059602 | 2.80732217 | CS |
260 | -7.28 | -72.8 | 10 | 15.23 | 0.95 | 1020951 | 4.28526185 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約